Agenus Inc.

NASDAQ:AGEN

Biotechnology

Healthcare
$6.40 -0.17%

-$0.01 today

Market cap
$289.58M
Beta
1.54
P/E (TTM)
1.7
EPS (TTM)
$1.70
52W Low $2.71High $7.34

Volume 0.88M

Average 0.82M

AGEN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Agenus Inc.NASDAQ: AGEN

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 38.29M shares rose 56.5% year over year, ahead of the +50.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 8.4% from the prior quarter. Over 3 fiscal years it compounded at +28.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +56.5% holds above the trailing-twelve-month pace of +50.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
38.29M+8.4% QoQ
Last fiscal yearDec 2025
29.73M+38.5% YoY
LTMMar 2026
33.65M+50.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.5%——
1 year+38.5%——
3-year CAGR+28.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
29.73M USD
Year-over-year change
+38.5%
4-year CAGR
+27.0%

Weighted Avg Shares (Diluted) vs competitors

How AGEN compares with its peers on the latest reported figures

  • AGEN's LTM Mar 2026 weighted avg shares (diluted) of 33.65M shares is the 9th highest of the 10 companies compared; the peer median is 61.49M shares.
  • Its year-over-year change of +50.2% is the 4th highest of 9, against a peer median of +1.5%.
  • Over three fiscal years its annual growth of +28.3% compares with a peer median of +13.9%.
AGEN Competitors Peer median
Weighted Avg Shares (Diluted) for AGEN and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+211.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 202671.52M +0.4%+10.8%
PLRXPliant Therapeutics, Inc.LTM Mar 202661.49M +1.3%+13.5%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
HURATuHURA Biosciences, Inc.LTM Mar 202650.79M +127.0%+911.7%
AGENAgenus Inc.LTM Mar 202633.65M +50.2%+28.3%
TTRXTurn Therapeutics Inc.LTM Mar 202625.17M ——
Peer median (excluding AGEN) 61.49M+1.5%+13.9%

Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.67M98.02M156.31M103.46M114.2M
Cost of Revenue182.08M197.26M237.68M156.01M80.36M
Gross Profit113.59M(99.24M)(81.37M)(52.55M)33.84M
Gross Margin38.4%-101.2%-52.1%-50.8%29.6%
Research & Development178.61M0234.57M155.53M0
Selling, General & Admin76.36M81.01M78.74M71.88M54.39M
Operating Expenses87.84M80.19M78.18M67.92M54.39M
Depreciation & Amortization6.79M6.95M13.59M13.34M10M
EBITDA43.78M(161.85M)(145.92M)(101.3M)62.19M
EBITDA Margin14.8%-165.1%-93.4%-97.9%54.5%
Operating Income25.75M(179.43M)(159.55M)(120.48M)(20.56M)
Operating Margin8.7%-183.0%-102.1%-116.4%-18.0%
Interest Income00000
Interest Expense65.72M61.86M97.93M117.63M55.27M
Other Income / Expenses(54.47M)(51.23M)(97.89M)(111.8M)17.47M
Income Before Tax(28.72M)(230.66M)(257.44M)(232.27M)(3.08M)
Pre-Tax Margin-9.7%-235.3%-164.7%-224.5%-2.7%
Income Tax Expense00000
Net Income(23.93M)(220.07M)(245.76M)(227.21M)115K
Net Margin-8.1%-224.5%-157.2%-219.6%0.1%
EPS (Basic)(2.11)(15.64)(13.75)(10.59)(0.00)
EPS (Diluted)(2.11)(15.64)(13.75)(10.59)(0.00)
Weighted Avg Shares11.45M14.09M17.89M21.47M29.73M
Weighted Avg Shares (Diluted)11.45M14.09M17.89M21.47M29.73M

Agenus Inc.

NASDAQ:AGEN

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.